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Methods S1. Systematic Search and Study Selection
We conducted a systematic search of Medline and EMBASE, last updated on February 21, 2013, without language restriction, using the following terms:
("adiponectin" [ Studies were excluded if: 1) they were non-human studies, commentaries, or reviews; 2) adiponectin was not an exposure; 3) hypertension was not an outcome; and 4) they were conducted in children, adolescents, or pregnant women. Additionally excluded were 6 studies [1] [2] [3] [4] [5] [6] that only included patients with specific conditions (diabetes mellitus, coronary heart disease, or end-stage renal disease) in whom the relationship between adiponectin and hypertension might differ; 3 studies 7-9 that excluded hypertensive participants; 1 study 10 that examined cardiac tissue adiponectin; 4 studies [11] [12] [13] [14] in which hypertension was not the outcome; and 3 studies [15] [16] [17] that were duplicate publications from the same cohort. [18] [19] [20] Two investigators (DHK and CK) independently screened abstracts and papers. Any disagreement was resolved by consensus. Finally, 48 studies were included in our systematic review.
Of 48 included studies, 43 were non-prospective (cross-sectional and retrospective case-control studies) and 5 were prospective (prospective case-control and cohort studies). Adiponectin levels by hypertension status were reported in 37 studies that contributed 47 data points: some reported data by sex, 21-25 obesity, 26, 27 menopausal status, 28 or ethnicity. 29, 30 Dose-response data were available or could be calculated in 16 studies (14 data points 24, 30-40 for 1 g/ml increase in adiponectin level and 12 data points 21, 24, 28, 30, [32] [33] [34] 36 , 41, 42 for 1 log e [ln] g/ml increase in adiponectin level). Of these studies, 7 studies 24, 30, 32-34, 36, 42 provided 9 data points on quantile-specific odds ratios (ORs) of hypertension, including gender-specific 36 and race-specific 30 data in 2 studies; 5 studies only reported OR per 1 g/ml change 31, [37] [38] [39] [40] ; and 3 studies only reported OR per 1 ln g/ml change.
21, 28, 41
Methods S2. Assessment of Study Quality
Study quality was assessed in the following domains: 1) representativeness of source population; 2) higher chance of potential selection bias; 3) reporting of assay methods; 4) outcome ascertainment; 5) confounding adjustment; 6) declaration of conflict of interest; and 7) description of the role of funding source. These items were modified from a previously proposed quality scale. 43 We assessed each item individually and as a composite score (0-7). Insufficient information to judge its adequacy was rated as inadequate quality.
1) Representativeness of source population:
Were participants drawn from a well-defined cohort or a community versus from clinics or hospitals?
2) Higher possibility of potential selection bias:
Cross-sectional studies: Did participation rates differ by outcome status? Case-control studies: Do controls represent the adiponectin distribution of the study base? Cohort studies: Did the proportion of loss to follow-up differ by exposure group?
3) Reporting of assay methods:
Did a study report at least two of the following aspects: a) description of collection, process, and storage of the sample; b) blinding of laboratory personnel; and c) the use of quality control sample or reporting coefficients of variation?
4) Outcome ascertainment:
Was hypertension status determined based on repeated visits versus single visit?
5) Confounding adjustment:
Were age, gender, and body mass index adjusted for?
6) Declaration of conflict of interest 7) Description of the role of funding source
Methods S3. Subgroup and Sensitivity Analyses
Several additional analyses were carried out to evaluate the sources of between-study heterogeneity and assess potential biases. First, we performed stratified analyses and meta-regression to examine the sources of between-study heterogeneity by the following study characteristics: study design, age group (<50, 50-59, or ≥60 years), proportion of male (male only, female only, or both), assay method (enzyme-linked immunosorbent assay versus radioimmunoassay), outcome type (prevalent versus incident hypertension), use of antihypertensive medication at the time of sampling, and body mass index category (<25, 25-29, or ≥30 kg/m 2 ). Second, we assessed the influence of the following quality components: representativeness of source population, higher chance of potential selection bias, reporting of assay methods, outcome ascertainment, and confounding adjustment. We did not examine the declaration of conflict of interest and description of the role of funding source individually, because most studies did not report them. We also evaluated whether the results differed between high-quality studies (composite quality score ≥ 5) and low-quality studies (score < 5). Third, we assessed the influence of individual studies on the pooled estimates by excluding 1 study at a time. Finally, we examined a possibility of publication bias by contour-enhanced funnel plot, 44 the Begg adjusted rank correlation test, 45 the Egger regression test, 46 and the trim-and-fill methods (METATRIM command). parameters in the british regional heart study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. Abbreviations: BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; NA, not applicable; NR, not reported. * Sample size for case-control and nested case-control studies were presented in number of cases / number of controls. 5.6 ± 2.7 g/ml 7.9 ± 3.0 g/ml Adiponectin level was inversely associated with blood pressure status (p=0.002). M: 6.7 ± 2.6 g/ml F: 8.5 ± 3.9 g/ml M: 4.8 ± 2.0 g/ml F: 7.1 ± 2.6 g/ml Adiponectin level was significantly higher in cases than in controls among men (p=0.01), but not among women (p=0.28). 9.9 ± 9.8 g/ml 12.9 ± 9.5 g/ml Adiponectin level was significantly lower in cases than in controls (p=0.02). 6.0 ± 3.6 g/ml 6.7 ± 3.9 g/ml Adiponectin level was significantly lower in cases than in controls (p<0.05). White: 7.3 ± 3.3 g/ml Black: 4.9 ± 2.4 g/ml White: 7.8 ± 3.2 g/ml Black: 5.4 ± 2.6 g/ml Abbreviations: BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HMW, high-molecular weight; HOMA-IR, the homeostasis model assessment of insulin resistance index; HTN, hypertension; IS, insulinsensitive; IQR, interquartile range; IR, insulin-resistant; MA, microalbuminuria; MAP, mean arterial pressure; NA, not applicable; NR, not reported; OR, odds ratio; Post-M, post-menopause; Pre-M, pre-menopause; QUICKI, quantitative insulin sensitivity check index; SBP, systolic blood pressure; SD, standard deviation; SE, standard error; WC, waist circumference. * The 5 th percentile to 95 th percentile was presented, instead of interquartile range. † Data were provided by the authors. 
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